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Abstract This study examines the effects of the intracel-
lular protein FKBP12.6 on action potential and associated
K
+ currents in isolated adult rabbit ventricular cardiomyo-
cytes. FKBP12.6 was over-expressed by ~6 times using a
recombinant adenovirus coding for human FKBP12.6. This
over-expression caused prolongation of action potential
duration (APD) by ~30%. The amplitude of the transient
outward current (Ito) was unchanged, but rate of inactiva-
tion at potentials positive to +40 mV was increased.
FKBP12.6 over-expression decreased the amplitude of the
inward rectifier current (IK1) by ~25% in the voltage range
−70 to −30 mV, an effect prevented by FK506 or lowering
intracellular [Ca
2+] below 1 nM. Over-expression of an
FKBP12.6 mutant, which cannot bind calcineurin, pro-
longed APD and affected Ito and IK1 in a similar manner to
wild-type protein. These data suggest that FKBP12.6 can
modulate APD via changes in IK1 independently of
calcineurin binding, suggesting that FKBP12.6 may affect




The development of the immunosuppressant drug FK506
resulted in the identification of a family of intracellular
proteins termed FK506 binding proteins (FKBP) [12]. The
12.6-kDa member of this family (FKBP12.6) binds to and
inhibitstheenzymecalcineurin,aCa
2+/calmodulin-dependent
phosphatase [19]. The FK506-FKBP12.6 complex cannot
bind to calcineurin; thus, FK506 treatment will dis-inhibit the
enzyme. In mammalian heart muscle, FKBP12.6 also binds
to and modulates the activity of the ryanodine receptor type
2( R y R 2 ) ,aC a
2+ channel in the sarcoplasmic reticulum (SR)
[20]. FKBP12.6 is thought to play an important role in
modulating the process of Ca
2+-induced Ca
2+ release from
the SR [14, 15], a key process in excitation–contraction
(E–C) coupling. Modulation of RyR2 activity by FKBP12.6
is not via effects on calcineurin; instead, the effects are
thought to be via direct interaction of the two proteins [21].
But RyR2 may not be the only cellular target for FKBP12.6
in heart cells. Indirect evidence for alternative targets comes
from studies showing that FK506 treatment prolongs the
action potential duration (APD) in isolated rat cardiomyo-
cytes [7, 9]. This effect is a consequence of the inhibition of
a number of currents including transient outward current
(Ito), delayed rectifier (IK) and inward rectifier (IK1)[ 8, 9].
Although these studies suggest a link between FKBP12.6
and K
+ currents in the heart, the work with FK506 cannot
distinguish between two options: (1) a direct effect of the
drug on the channels or (2) an effect mediated via FKBP.
This study examines the effects of FKBP12.6 over-
expression in adult rabbit cardiomyocytes on the action
potential, the inwardly rectifying potassium current (IK1)a n d
the transient outward current (Ito) .T h ed a t ai n d i c a t et h a t
FKBP12.6 can regulate IK1 in the physiological voltage
range in a manner that is independent of calcineurin binding.
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Isolation of adult ventricular rabbit cardiomyocytes
Adult rabbit ventricular cardiomyocytes were isolated from
New Zealand White rabbits by standard enzymatic disso-
ciation as described previously [16]. In brief, animals were
anaesthetised using sodium pentobarbital (100 mg/kg) with
1,000 IU heparin. The aorta was rapidly cannulated after
the heart was removed and perfused in Langendorff mode
with a Ca
2+-free Krebs solution (pH 7.4 with NaOH)
consisting of (mM): 120.0 NaCl, 20.0 4-2-hydroxyethyl-1-
piperazineethanesulfonic acid (HEPES), 5.4 KCl, 0.52
NaH2PO4, 3.5 MgCl2⋅6H20, 20.0 taurine, 10.0 creatine,
11.1 glucose. After sufficient perfusion, the Ca
2+-free Krebs
was switched to Krebs containing 0.05 mM Ca
2+ plus
collagenase and protease for 5.5 min. Finally, perfusion was
changed to a 1% bovine serum albumin 0.075 mM Ca
2+
Krebs solution. The digested left ventricle was removed
from the cannula, cut into small pieces and agitated in
0.125 mM Ca
2+ solution for 1 h. Consequently, the
myocytes were re-suspended in a series of Krebs solution
containing (mM) 0.25, 0.5 and 1 Ca
2+.
Adenoviral transfection and cell culture
Recombinant adenoviruses were generated using standard
procedures [16]. Briefly, a human heart muscle-specific
cDNA sample was used to clone full-length cDNA of the
human FKBP12.6 gene (Fig. 4a) by using polymerase chain
reaction (PCR) and PCR primers to span the coding region
of FKBP12.6 cDNA. Three populations of adenovirus-
transfected myocytes were cultured to overexpress: (1) β-
galactosidase (Ad-LacZ), (2) FKBP12.6 (Ad-FKBP21.6)
and (3) a mutant form of FKBP12.6 (Ad-FKBP12.6 m) that
cannot bind calicneurin (see below). Myocytes were trans-
fected with a multiplicity of infection (MOI) of 100.
Transfected myocytes were subsequently incubated in a
supplemented medium, M199 (Sigma), for 24 h, at 37°C.
Verification of FKBP12.6 expression and virus transfection
efficiency has been detailed elsewhere [14, 16]. Previous
measurements suggest that the level of FKBP12.6 over-
expression was approximately 6× normal values (Fig. 4b( i ) )
[16].
Mutant FKBP12.6
The FKBP12.6 mutant was constructed by the site-directed
mutagenesis of the wild-type FKBP12.6, resulting in a
G89P V90K mutant and the deletion of the calcineurin
binding site (Fig. 4a). The mutant was tested for protein and
DNA levels (Fig. 4b (ii) and c). The full-length FKBP12.6 m
cDNA sequence was inserted downstream from a cytomeg-
alovirus promoter into vector pACCMV·pLpA, and recom-
bination with vector pJM17 was performed in HEK293 cells.
The production, purification and titration of adenovirus
containing the FKBP12.6 gene (Ad-FKBP12.6) were per-
formed according to standard procedures [1].
Solutions
The isolated cardiomyocytes were allowed to settle on the
base of a recording chamber mounted on the stage of an
inverted microscope and superfused with a HEPES-based
Krebs–Heinseleit solution consisting of (mM): 144.0 NaCl,
5.4 KCl, 0.3 NaH2P04, 1.0 MgCl2, 5.0 HEPES, 11.1
glucose and 1.8 CaCl2, (pH 7.4 with NaOH). For IK1
measurement, pipettes were filled with an intracellular
solution of composition (mM): 15 K aspartate (DL), 10
KCl, 10 HEPES, 4.5 MgCl2,4N a 2ATP, 1 Na2CrP, 25 K2–
ethyleneglycoltetraacetic acid (EGTA), 25 CaK2EGTA ,
free [Ca
2+] 170 nM, pH 7.25. In some experiments, 10 mM
K2EGTA was used (free [Ca
2+] <1 nM). For Ito measure-
ment, pipettes were filled with an intracellular solution of
composition (mM): 120 K aspartate (DL), 20 KCl, 5
HEPES, 4 Na2ATP, 1 MgCl2, 1 EGTA (pH 7.25 with
KOH). To block various channels, the following com-
pounds were used in the superfusate: cadmium chloride at
0.3 mM to block the calcium-sensitive component of Ito;
barium chloride at 0.2 mM to block the inward rectifier
(IK1) and TTX (Tetrodotoxin) at 3×10
−5 M to block INa.
Thapsigargin (5 μM) was included in the superfusate for a
sub-set of IK1 measurements. For action potential measure-
ment, pipettes were filled with an intracellular solution of
composition (mM): 120 KCl, 10 NaCl, 10 HEPES and 0.1
EGTA (pH 7.25). Microelectrodes were pulled from
boroscilicate glass (Clark Electromedical, Oxford, UK),
fire polished, and filled with the appropriate internal
solution when filled pipette resistance measured 3–6M Ω.
Electrophysiological protocols
Action potentials were elicited in current clamp mode using
a square pulse of 1 nA and 5 ms duration at 0.5 Hz. The
action potential duration was measured at10%,50% and 90%
of the repolarisation. In separate experiments, membrane
currents were measured in discontinuous (switch) voltage
clamp mode using the whole cell patch technique with an
Axoclamp 2A amplifier (Axon Instruments, Foster City, CA,
USA).Protocolswerecontrolled,recordedandanalysedusing
a PC and Axon Laboratory Software (Axon Instruments).
Ito is activated in response to depolarising steps and
comprises two components: the 4-AP-sensitive K
+ current
and the Ca
2+-sensitive chloride current [10]. In this study,
the Ca
2+-sensitive chloride component was blocked using
0.3 mM Cd
2+ [10]. Transient outward current (Ito) was
654 Pflugers Arch - Eur J Physiol (2009) 458:653–660studied by holding at a membrane potential of −80 mV
followed by a step to −40 mV for 50 ms in addition to TTX
to completely inactivate INa (Fig. 2a (i)). Ten millivolts
depolarising steps from −50 to +70 mV were applied for
500 ms duration at 0.1 Hz. Ito was measured as the
difference between peak Ito and the sustained outward
current at the end of the pulse [11, 13, 22]. Pharmacological
interventions to block Ito were not used in this study since
the effects are more wide ranging than exclusively to Ito
[17]. It has also been shown that the steady state current at
the end of the pulse is not affected by 4-AP [3]. The inward
rectifier (IK1) was studied by using a holding potential of
−80 mV with 10 mV steps from −100 to +100 mV for
750 ms duration at 0.2 Hz in the absence and then in the
presence of 0.25 mM Ba





Action potentials in response to brief current injections
were recorded in isolated rabbit cardiomyocytes from both
Ad-FKBP12.6 and Ad-LacZ groups. Figure 1a (i) shows
typical action potentials recorded from myocytes at 19–21°C
stimulatedat0.5Hzbybriefcurrentinjections.Astheaverage
data in Fig. 1b show, the duration of the action potential in
cardiomyocytes over-expressing FKBP12.6 was increased by
approximately 33% at both 90% of repolarisation (APD90)
and 50% of repolarisation (APD50), but there were no
significant effects at 10% of repolarisation (APD10). The
time from the stimulus until the repolarisation phase reached
zero millivolts (0 mV) was 173±17 ms (n=12) in Lac-Z
transfected cells and 213±26 ms (n=10) in cells over-
expressing FKBP12.6, but this difference did not reach
significance. Thus, the major affects on action potential
difference appeared to emerge in the repolarisation phase
beyond approximately 0 mV. Neither the resting membrane
potential nor the maximum rate of depolarisation was
significantly different between experimental groups (data
not shown).
Transient outward current (Ito)
Figure 2a (i) shows a typical Ito voltage record from a
myocyte transfected with Ad-LacZ. Figure 2a (ii) and (iii)
show typical Ito records from cells expressing AdLacZ and
AdFKBP12.6, respectively. The average Ito amplitude in
the Ad-LacZ and Ad-FKBP12.6 myocyte groups is shown
in Fig. 2b (i). Over-expression of FKBP12.6 did not cause a
significant change in peak Ito or the amplitude of the
transient component of Ito. The small remaining steady-state
component was increased in FKBP12.6 over-expression by
~63% across the voltage range (e.g. 0.0019 nA/pF vs.
0.0031 nA/pF at 30 mV P<0.05). The rate constant of decay
of the current was measured by fitting an exponential decay
to >80% of the current decay between peak and steady state.
Fig. 1 Effect of FKBP12.6 over-
expression on action potential
duration. a Individual action
potentials recorded from single
cardiomyocytes after transfection
with Ad-LacZ (black line)a n d
Ad-FKBP12.6 (grey line).
b Average action potential
duration at 90% (i),5 0 %(ii) and




Pflugers Arch - Eur J Physiol (2009) 458:653–660 655The value of the rate constant increased (Fig. 2b (ii)) at more
polarised potentials. FKBP12.6 over-expression resulted in a
significantly enhanced rate of decay at membrane potentials
more positive than +40 mV (48.4% increase at 50 mV,
48.2% at 60 mV and 49.6% at 70 mV; Fig. 2b (ii)).
Inward rectifier (IK1)
Figure 3a (i) shows a typical IK1voltage record from a
myocyte transfected with Ad-LacZ. Figure 3a (ii) and (iii)
show representative traces of Ba
2+-sensitive currents in an
Ad-LacZ and FKBP12.6 over-expressing cell, respectively.
The current displays the typical pronounced inward
rectification that is characteristic of IK1. The average IK1
currents over the range −80 mV to 0 mV for both the Ad-
LacZ and Ad-FKBP12.6 groups are shown in Fig. 3b (i).
FKBP12.6 over-expression significantly decreased the
magnitude of IK1 in the voltage range −70 to −30 mV.
These measurements were made using a pipette solution
containing ~170 nM Ca
2+, buffered with 50 mM EGTA to
ensure constant and standardised Ca
2+ levels between
experimental groups. The specificity of the effect of
transfection with Ad-FKBP12.6 was supported by the
observation that incubation with 10 μM FK-506 inhibited
the effect of FKBP12.6 over-expression (Fig. 3b (ii)). To
investigate the Ca
2+ sensitivity of the effects of FKBP12.6
over-expression, intracellular [Ca
2+] was lowered to <1 nM
by inclusion of (10 mM EGTA, no added Ca
2+) in the patch
pipette solution. As shown in Fig. 3b (iii), reducing the
cytoplasmic [Ca
2+] abolished the effect of FKBP12.6 over-
expression on IK1. To investigate the role of SR Ca
2+ release
on IK1, cardiomyocytes were perfused with the sarcoplasmic/
endoplasmic reticulum Ca
2+-ATPase (SERCA2A) blocker
Thapsigargin (~170 nM Ca
2+) to deplete the SR of Ca
2+.A s
illustrated in Fig. 3b (iv), depleting the SR Ca
2+ had no effect
on the magnitude of IK1.
To investigate the role of calcineurin in this response, a
mutant form of FKBP12.6 was generated (Fig. 4a) that was
unable to bind to calcineurin yet retained other properties of
the protein [18]. An adenovirus expressing FKBP12.6 m
was created (Ad-FKBP12.6 m) and tested for protein levels
(Fig. 4b (ii)) and DNA (Fig. 4c). As with the wild-type
protein, over-expression of the mutant form of the protein
caused a prolongation of the action potential (APD90:3 7 6 ±
19 ms (n=12) vs. 681±32 ms (n=15), Ad-LacZ vs. Ad-
FKBP12.6 m). As shown in Fig. 5a, the effects of Ad-
Fig. 2 Effect of FKBP12.6
over-expression on the transient
outward current (Ito). a A typical
family of voltage (i) and current
recordings from a single
Ad-LacZ cardiomyocyte (ii) and
Ad-FKBP12.6 cardiomyocyte
(iii). b (i) current–voltage
relationship in Ad-LacZ (open
circles; n=19) and Ad-
FKBP12.6 (closed circles;
n=20). (ii) Rate constant of
decay of Ito in Ad-LacZ (open
circles, n=19) and Ad-
FKBP12.6 (closed circles,
n=20). *P<0.05
656 Pflugers Arch - Eur J Physiol (2009) 458:653–660FKBP12.6 m transfection did not significantly alter Ito
amplitude, whilst the rate constant for decay showed a non-
significant trend to increase over the physiological range of
membrane voltages. Over-expression of the mutant form of
FKBP12.6 inhibited IK1 (Fig. 5b (i)) in a similar fashion to
the wild-type protein. FKBP12.6 m over-expression signif-
icantly decreased the magnitude of IK1 in the voltage range
−70 to −10 mV. This effect was inhibited by prior incubation
with the drug FK506 (Fig. 5b (ii)), and the effect was absent
when intracellular [Ca
2+] was lowered to <1 nM (Fig. 5b
(iii)).
Discussion
In this study, the effects of over-expression of FKBP12.6 on
the action potential and two of the underlying K
+ currents
were studied in isolated adult rabbit cardiomyocytes. Over-
expression of FKBP12.6 prolonged the action potential
significantly. The differences between action potentials
recorded from the two groups showed significant differences
in the latter phases of the repolarisation more negative to
0 mV. Previous work has shown that neither ICa,L nor NCX
(Sodium-Calcium exchanger) are affected by acute upregu-
lation of FKBP12.6 in the intact cardiomyocyte [14];
therefore, modulation of K
+ currents is the most likely
explanation for the effect.
Effects of FKBP12.6 over-expression on Ito
FKBP12.6 over-expression does not have significant effects
on the peak current, the amplitude of the transient
component or the voltage dependence of Ito However, the
small remaining steady-state component was significantly
Fig. 3 Effect of FKBP12.6
over-expression on the inward
rectifier (IK1). b A typical family
of voltage (i) and current
recordings from a single
Ad-LacZ (ii) and a single
Ad-FKBP12.6 cardiomyocyte
(iii). b (i) Average current–
voltage relationships for cardio-
myocytes from Ad-LacZ (open
circles, n=10) and Ad-
FKBP12.6 groups (closed
circles, n=11). The patch pipette
solution was buffered at 170 nM
Ca
2+ with 50 mM EGTA. (ii)
Average current–voltage
relationships for cardiomyocytes
from Ad-LacZ (open circles,
n=10) and Ad-FKBP12.6
(closed circle, n=12) on
incubation with 10 μM FK-506.
(iii) Average current–voltage
relationships for cardiomyocytes
from Ad-LacZ (open circles,
n=10) and Ad-FKBP12.6
groups (closed circles, n=11)
recorded using a pipette solution




perfused with normal perfusate
(~170 nM Ca
2+; closed squares,
n=6) and perfusate containing
5 μM Thapsigargin (closed
triangles, n=6). **P<0.05
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positive potentials (>+40 mV), the rate of inactivation after
FKBP12.6 expression was enhanced compared to the
control values. Ito is active during phase 1 of the cardiac
action potential, and drug-induced reduction of Ito is known
to prolong action potential duration [2]. A more rapid
inactivation (as observed after FKBP12.6 over-expression)
might be expected to prolong the action potential duration,
but this link has not been reported. Furthermore, the effect
of FKBP12.6 on Ito inactivation was observed at potentials
more positive than +40 mV, i.e. beyond the range of
voltages experienced normally during an action potential. In
this study, action potential duration was not significantly
prolonged at 0 mV on the repolarisation phase. Significant
prolongation was observed at 50% of repolarisation (ap-
proximately −20 mV) and 90% repolarisation (approxi-
mately −70 mV). These potentials are considerably more
negative than the potentials at which Ito were affected.
Therefore, it is unlikely that the changes in Ito are responsible
for the observed changes in action potential duration.
Effects of FKBP12.6 over-expression on IK1
The shape and magnitude of IK1 current–voltage relation-
ship shown in this study is similar to those published
previously [4, 6]. FKBP12.6 over-expression caused a
significant decrease of approximately 25% in the amplitude
of IK1 within the voltage range of −70 to −30 mV. At
potentials positive to 0 mV, IK1 currents were not
significantly different from zero in both experimental
groups. The conditions under which this decrease in IK1
amplitude was observed (170 nM Ca
2+, 50 mM EGTA)
would prevent FKBP12.6 induced changes in RyR2 activity
that would alter the intracellular Ca
2+ both in the bulk
cytoplasm and also locally next to the sarcolemma. This
indicates that RyR2 is not involved in the action of
FKBP12.6 on IK1. This is further supported by the lack of
effect upon depleting the SR of Ca
2+ using Thapsigargin,
suggesting that the effect of FKBP12.6 over-expression is
not via modulation of RyR2 activity.
The effects of FKBP12.6 over-expression were abol-
ished by incubation with the drug FK506. This supports the
view that the effect of FKBP12.6 over-expression was due
to a specific interaction. The magnitude of IK1 in both Ad-
LacZ and Ad-FKBP12.6 groups between −60 mV and
−30 mV was on average smaller in the presence of FK506,
by ~50% (Ad-LacZ group) and ~45% (FKBP12.6 over-
expression group; P<0.05 at −30 mV). FK506-mediated
depression of IK1 was previously reported in rat cardio-
myocytes [9]. This result appears counter-intuitive since
FKBP12.6 over-expression decreased IK1, removal of
FKBP12.6 with FK506 would be expected to increase IK1
(i.e. the opposite of the observed effects). Therefore, the
depressive effect of FK506 on IK1 may result from an
action of the drug on IK1 independent of FKBP12.6. This
effect appears to dominate over the enhancement of IK1 as a
result of FKBP12.6 removal.
The mode of action of FKBP12.6 on IK1 is not known;
one possibility is that this effect is mediated by phosphor-
Fig. 4 FKBP12.6 and FKBP12.6 mutant. a Amino acid sequence of
human FKBP12.6 and indication of the insertion of the mutation made
to the calcineurin binding site. b Western immunoblot analysis of (i)
Ad-LacZ (LacZ)-infected and Ad-FKBP12.6-GFP (FKBP12.6)-
infected myocytes and (ii) Ad-FKBP12.6 m-GFP (FKBP12.6)-
infected myocytes. Cells were infected with indicated MOI and
harvested after 48 h of culture time. FKBP12.6 protein expression
increases with increasing virus titres. The fact that FKBP12.6 migrates
as a broad band during electrophoresis and could not be clearly
separated from endogenous FKBP12 is most likely attributable to the
lysis procedure of the cells under high-salt conditions. b RT-PCR
analysis of Ad-FKBP12.6 m infected myocytes. Cells infected at
indicated MOI and harvested 48 h post transfection. (+) denotes
positive control with FKBP12.6 plasmid DNA as template
658 Pflugers Arch - Eur J Physiol (2009) 458:653–660ylation of IK1 via inhibition of calcineurin [5]. However, a
decrease in IK1 was evident in experiments involving the
mutant form of FKBP12.6 (Fig. 5) indicating that calcineurin
was not involved in the effect. It is however interesting to
note that the magnitude of the effect of FKBP12.6 m on
action potential duration and IK1 was much larger than the
native protein. Whilst the conditions of culture with both
adenoviruses was the same, the over-expression of the two
forms of the protein was not quantified with sufficient
precision to be confident that this effect was not simply the
result of higher intracellular levels of the mutant protein.
Alternatively, the mutation could alter the relative affinity of
FKBP12.6 for the target protein; further work is required to
distinguish these two options.
Removal of Ca
2+ from the cytosol significantly increased
IK1 and abolished the ability of FKBP12.6 to modulate IK1.
Data indicating an inhibitory effect of intracellular Ca
2+ on
IK1 have previously been reported [23], but this modulating
influence has not been extensively studied. The molecular
basis for the Ca
2+ dependency of the action of FKBP12.6
deserves further investigation. Both FK506 and low Ca
2+
appear to acutely prevent the ability of FKBP12.6 to affect
IK1. This suggests that FKBP12.6 modulates IK1 via
changes in the biophysical properties of the channel
(including the Ca
2+ sensitivity), rather than ion channel
expression.
In summary, this paper shows for the first time that
FKBP12.6 over-expression decreases IK1 in a Ca
2+-depen-
dent and FK506-sensitive fashion. No major effects of
FKBP12.6 were observed on the Ito amplitude. This
suggests a role for this cytoplasmic protein in addition to
the known effects on the RyR2. Thus, altered expression
and binding of FKBP12.6, as is known to occur in heart
failure [15], may alter E–C coupling indirectly via changes
in the action potential duration in addition to effects on the
RyR2.
Fig. 5 Effect of FKBP12.6
mutant over-expression on Ito
and IK1. a (i) Average Ito
current–voltage relationships for
cardiomyocytes from Ad-LacZ
(open circles, n=10) and
Ad-FKBP12.6 m groups (closed
circles, n=11). (ii) Rate constant
of decay of Ito from Ad-LacZ
(open circles, n=10) and
Ad-FKBP12.6 m (closed circle,
n=11). b (i) Average IK1
current–voltage relationships for
cardiomyocytes from Ad-LacZ
(open circles, n=13) and
Ad-FKBP12.6 m groups (closed
circles, n=13) recorded using a
pipette solution containing
170 nM Ca
2+. (ii) Average IK1
current–voltage relationships for
cardiomyocytes from Ad-LacZ
(open circles, n=13) and
Ad-FKBP12.6 m groups (closed
circles, n=13) recorded upon
incubation with FK506. (iii)
Average IK1 current–voltage
relationships for cardiomyocytes
from Ad-LacZ (open circles,
n=10) and Ad-FKBP12.6 m
groups (closed circles, n=11)
recorded using a pipette solution
containing <1 nM Ca
2+.
**P<0.01, ***P<0.001
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